CureVac AG, which is developing messenger RNA-based vaccines, has appointed Daniel Menichella as chief executive officer of its Boston, Massachusetts subsidiary CureVac Inc. Mr Menichella was previously chief business officer at Bamboo Therapeutics Inc, a gene therapy company acquired by Pfizer Inc in 2016. At CureVac he will focus on expanding the German company’s US business network. The company’s mRNA therapies are in clinical development for two cancer indications and as a prophylactic against rabies. Mr Menichella has held business development jobs at a number of US companies as well as at Merck KGaA.
CureVac announced the appointment on 2 May 2017
Copyright 2017 Evernow Publishing Ltd